Northwest Biotherapeutics, Inc. filed a Form 8-K on October 30, 2026, disclosing that it entered into a Commercial Loan Agreement and Note with Streeterville Capital, LLC on October 26, 2026, for $5,505,000.

Key Highlights

  • Loan amount: $5,505,000 from Streeterville Capital, LLC, dated October 26, 2026.
  • Maturity: 22 months, with no repayments required for the first 8 months.
  • Amortization: Beginning June 26, 2027, repaid in 14 equal monthly installments at 110% of the pro rata principal amount, plus accrued interest.
  • Interest rate: 8% per annum, with an original issue discount of ten percent.
  • Pre-payment option: The company may pre-pay at any time, subject to a 10% charge.
  • Use of funds: Proceeds designated for the company's ongoing business operations, according to the filing.

Northwest Biotherapeutics Enters 22-Month Commercial Loan with Streeterville Capital

According to the Form 8-K filed with the SEC on October 30, 2026, Northwest Biotherapeutics, Inc. (OTCQB:NWBO) entered into a Commercial Loan Agreement and Note with Streeterville Capital, LLC on October 26, 2026. The total loan amount is $5,505,000, and the agreement carries a maturity of 22 months. The filing disclosed that no repayments are required during the first 8 months of the loan's term.

The filing stated that beginning June 26, 2027, the loan will be amortized over 14 equal monthly installments of principal at 110% of the pro rata amount, plus accrued interest. Interest accrues at a rate of 8% per annum. The loan also carries an original issue discount of ten percent. The company disclosed that the Loan Agreement allows pre-payment at any time at its election, though any pre-payment would include a 10% charge.

The filing noted that the Loan Agreement "contains customary default provisions, including for potential acceleration." The company reported that the funds will be used for its ongoing business operations. The Form 8-K was signed by Linda Powers, Chief Executive Officer and Chairman, on October 30, 2026. The disclosure was made under both Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation).

What Was Disclosed

Northwest Biotherapeutics disclosed a $5,505,000 commercial loan from Streeterville Capital, LLC with a 22-month maturity, an 8% annual interest rate, a ten percent original issue discount, a deferral period of 8 months before payments begin, and a 10% pre-payment charge if the company elects early repayment.